Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Syndrome

Polycystic Ovary Syndrome

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

Oculocerebral Syndrome With Hypopigmentation

Coagulants

All Drugs and Chemicals

Factor VIII

Somatomedin B

several thrombotic biological marker will be dosed in blood. (C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)

Thrombotic profile

Justine Hugon Rodin, MD

Hélène BEAUSSIER, PharmaD

Juliette COURTIADE MAHLER

Hélène Beaussier, pharmaD

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of childbearing age. PCOS can be individualized into several phenotypes, taking into account in particular the presence of hyperandrogenism, insulin resistance and BMI. Hyperandrogenism and insulin resistance appear to be important factors in the development of cardiovascular cardiovascular disease. In addition, patients frequently use anti-androgenic and/or contraceptive treatments contraceptives, such as combined hormonal contraception (CHC), the use of which is associated with an increased cardiovascular and thrombo and venous thrombosis (VTE). A meta-analysis published in 2020 by Gariani et al.

based on three large studies, estimated the risk of VTE in women with PCOS after adjustment for obesity and hormone therapy. This risk was significantly higher compared with women without PCOS (pooled OR 1.89, CI95% 1.60-2.24). No study has looked specifically investigated the risk of VTE according to different PCOS phenotypes. Such data would be very useful in clinical practice, as it would enable monitoring, contraceptive treatment and anti-androgenic anti-androgen treatment according to the PCOS phenotype, while limiting risks. Assessing the differences PCOS phenotypes is limited by the large sample size required. required. VTE is a rare event in women of childbearing age, and the number of PCOS phenotypes is high.

PCOS phenotypes. Intermediate markers of VTE risk are used in these situations. These markers are thrombin generation tests (notably ETP) and their sensitivity to activated protein C (nAPCsr) and thrombomodulin (nTMsr), as well as sex-hormone binding globulin (SHBG).

Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study

Evaluation of the biological procoagulant profile in women of childbearing age with PCOS, in relation to the presence or absence of insulin resistance, by comparing FTE levels between women with PCOS and women without PCOS. the presence or absence of insulin resistance, by comparing ETP levels between women with PCOS without and with insulin resistance

Estimate the prevalence of overweight, obesity, and insulin resistance in women with with PCOS

comparison of procoagulant biomarker for women with or without insulin resistance

comparison of procoagulant biomarker for women with or without hyperangrogenism

comparison of procoagulant biomarker depending on PCOS phenotype

comparison of procoagulant biomarker depending on AMH Rate

comparison of PCOS-QoL, SF36 and HADS scores depending on PCOS phenotype

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study	NCT06339567	Polycystic Ovar...	Thrombotic prof...	18 Years - 35 Years	Fondation Hôpital Saint-Joseph
Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study	NCT06339567	Polycystic Ovar...	Thrombotic prof...	18 Years - 35 Years	Fondation Hôpital Saint-Joseph
Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study	NCT06339567	Polycystic Ovar...	Thrombotic prof...	18 Years - 35 Years	Fondation Hôpital Saint-Joseph

Spots Global Cancer Trial Database for thrombotic profile